GFAP upregulation is one of the most consistent pathological changes in AD and is considered a promising biomarker (Askenazi et al. 2023; Grande 2025; Serrano-Pozo et al. 2024; Bellaver et al. 2023). The gene discussed is GFAP; the disease is Alzheimer disease.